



NDA 15923/S-094
NDA 18701/S-072

SUPPLEMENT APPROVAL

Janssen Research & Development, LLC
Attention: Mary Mulligan
Associate Director, Global Regulatory Affairs
920 U.S. Highway 202, P.O. Box 300
Raritan, NJ 08869-0602

Dear Ms. Mulligan:

Please refer to your Supplemental New Drug Applications (sNDA) dated January 22, 2016, and received January 27, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NDA 15923 Haldol (haloperidol) Injection (for immediate release) 5 mg/ml and NDA 18701 Haldol (haloperidol decanoate) Intramuscular Injection 50 mg/ml and 100 mg/ml.

These “Changes Being Effected” supplemental new drug applications provide for the addition of the adverse reaction term “rhabdomyolysis” to the **ADVERSE REACTIONS/Postmarketing Events** section of labeling for Haldol Injection and Haldol Intramuscular Injection.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Simran Parihar, PharmD, at simran.parihar@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:

Contents of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
05/18/2016